Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg.
about
Assessment and management of behavioral and psychological symptoms of dementiaChanges in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trialImplementation of warnings from Dear Doctor Letters (Rote-Hand-Briefe): an analysis of medication data from a large cohort of elderly patientsEvaluation of Changes in Citalopram Prescribing Patterns Following a US Food and Drug Administration Alert: A Retrospective Cohort Study.Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.A systematic approach to pharmacotherapy for geriatric major depressionWhich adverse effects influence the dropout rate in selective serotonin reuptake inhibitor (SSRI) treatment? Results for 50,824 patientsStimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS)Effects of Escitalopram on Autonomic Function in Posttraumatic Stress Disorder Among Veterans of Operations Enduring Freedom and Iraqi Freedom (OEF/OIF).Risk of Ventricular Arrhythmia with Citalopram and Escitalopram: A Population-Based Study.Use of selective serotonin re-uptake inhibitors and the heart rate corrected QT interval in a real-life setting: the population-based Rotterdam Study.Antidepressant use and risk of cardiovascular outcomes in people aged 20 to 64: cohort study using primary care databasePsychotropic Drugs and Prolonged QTc Interval: Does it Really that Matter?How much to worry about the FDA warning in the use of citalopram?Antidepressant and QT interval prolongation, how should we look at this issue? Focus on citalopram.Evidence behind FDA alerts for drugs with adverse cardiovascular effects: implications for clinical practice.CYP2C19 variation, not citalopram dose nor serum level, is associated with QTc prolongation.Management of treatment-resistant depression in children and adolescents.Safety of selective serotonin reuptake inhibitor treatment in recovering stroke patients.Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines.Management of depression after myocardial infarction.Update on SSRI Treatment for Neuropsychiatric Symptoms of Dementia.Pharmacotherapy of major depression in late life: what is the role of new agents?High-Dose Citalopram and Escitalopram and the Risk of Out-of-Hospital Death.The effectiveness and limitations of regulatory warnings for the safe prescribing of citalopram.Treated Behavioral Symptoms and Mortality in Medicare Beneficiaries in Nursing Homes with Alzheimer's Disease and Related Dementias.Inappropriate pharmacological treatment in older adults affected by cardiovascular disease and other chronic comorbidities: a systematic literature review to identify potentially inappropriate prescription indicators.Predictors of PTSD Symptom Change Among Outpatients in the U.S. Department of Veterans Affairs Health Care System.QT interval and dispersion in drug-free anorexia nervosa adolescents: a case control study.Risk of Cardiac Events Associated With Antidepressant Therapy in Patients With Long QT Syndrome.Frequency of use of QT-interval prolonging drugs in psychiatry in Belgium.Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology.A comparative study of QT prolongation with serotonin reuptake inhibitors.Monitoring of somatic parameters at outpatient departments for mood and anxiety disorders
P2860
Q28088782-E183D7FF-6B73-4ABF-BF09-AF6A0057D498Q28539543-10B80031-DAFA-4750-8983-49BB17BB465DQ30810766-F6019409-E2DF-42DF-8D74-B05C405FC62FQ33165968-5EE9BCC0-32F5-4FB7-91D4-D47C9E504581Q33863623-40E87E1F-275B-4AD2-AA3D-5B6C3E7493D9Q34004408-C685804A-3B11-4746-BB2E-49ACE75BC03EQ34368534-82EC23A5-4F84-4CF9-9E80-5EBBFD7A74F6Q34389980-4F7DA165-6993-426B-9BEB-7C4C04123506Q35776730-1B64CBBA-3328-4C07-ABDA-BB3992B5CB70Q36101440-7AFB1C1C-F36C-4F4A-9C5B-27AE248852DCQ36125470-A108C673-2751-4268-A035-760D763808FDQ36719034-291F40EE-E7AC-4935-9B6D-1746AC0EAF56Q36764542-FB5027AE-EF9B-4AD5-BB42-490B1E587369Q38130550-3CA40785-D6D3-414E-B841-99666C0AE168Q38153098-A0F20367-2EDA-45C6-B632-A5783C8219DCQ38172025-D5077257-07E4-4CBF-9267-A6EB2A5A807FQ38239777-64BB31A6-E3E8-4984-9BB8-85635DDA24EAQ38247062-7713D1A8-7E6A-405A-8176-1ADD79F2F1A2Q38402064-9BE20FBD-1C4F-4720-B204-4C028140EC3FQ38476909-176CD809-E27D-4873-92CC-059EE973A8F1Q38567458-2BF41898-F67D-4F6B-AF9A-B7276837822FQ38701753-1CB29C07-F07D-49AB-832D-AF97F1F7FA87Q38894956-54E04F2E-84A1-4EB0-960D-F4DF6F541D3FQ40543775-5B03955A-6B88-4E46-93FF-3414004D7868Q40597331-27F5016A-3CEB-4096-B89E-771530F5883BQ40603961-10839D3F-E05E-42FC-BE54-7CB810898CA9Q43063161-D856D13D-1196-4680-8D6B-6D81213BAA0EQ45326953-B24BED40-6BD1-479B-BF2B-A1DABCF29799Q47573529-D8D8FE1A-D392-4FD0-9C78-B1D95B41BC0DQ49645667-96274470-B443-4DA5-97C6-A05BD08D9615Q50644981-6A686EE0-A42A-4082-B8D9-F1D19DDE7CEBQ53091817-1E1BE52C-14C4-4B4E-B253-8492895A330EQ53811350-DFC6BB69-4BA1-4D10-BC19-349755C4198DQ58731395-90797116-2F53-4B52-A541-DB84DC43B6A3
P2860
Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg.
@ast
Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg.
@en
Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg.
@nl
type
label
Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg.
@ast
Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg.
@en
Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg.
@nl
prefLabel
Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg.
@ast
Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg.
@en
Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg.
@nl
P2093
P1476
Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg.
@en
P2093
Amy S B Bohnert
Brahmajee K Nallamothu
Dara Ganoczy
Frederic C Blow
Helen C Kales
Kara Zivin
Paul N Pfeiffer
P304
P356
10.1176/APPI.AJP.2013.12030408
P407
P577
2013-06-01T00:00:00Z